Explore Groundbreaking Research on PRRT Toxicity and Survival (Internet Services - Other Internet Services)
USAOnlineClassifieds > Internet Services > Other Internet Services
Item ID 2831645 in Category: Internet Services - Other Internet Services
Explore Groundbreaking Research on PRRT Toxicity and Survival | |
Are you or a loved one navigating treatment options for metastatic neuroendocrine tumors (NETs)? A new study sheds light on the safety and efficacy of Peptide Receptor Radionuclide Therapy (PRRT), comparing two agents—177Lu-DOTATATE and 90Y-DOTATOC—to optimize patient care and outcomes. Key Insights You'll Discover: • Minimal Renal Toxicity: Stable renal function observed with both PRRT agents. • Hematological Effects: 177Lu-DOTATATE linked to minor blood cell and platelet reductions. • Progression-Free Survival (PFS): 177Lu-DOTATATE improves PFS significantly compared to 90Y-DOTATOC. • Overall Survival (OS): No significant OS difference between the treatments. • Monitoring Needs: Regular blood health assessments are crucial during PRRT. Why It Matters: This cutting-edge research highlights how PRRT can extend disease progression while maintaining safety, empowering patients and providers to make informed treatment decisions. Learn More About: • The differences in efficacy between 177Lu-DOTATATE and 90Y-DOTATOC. • How personalized care can improve quality of life for NET patients. • The importance of monitoring and managing side effects for better outcomes. Visit Our Website to read the full study and gain valuable insights into this life-changing therapy. https://mdnewsline.com/comparing-prrt-agents-in-neuroendocrine-tumors-toxicity-and-survival/  | |
| Related Link: Click here to visit item owner's website (0 hit) | |
| Target State: All States Target City : All Cities Last Update : Dec 23, 2024 7:22 AM Number of Views: 18 | Item Owner : MDNewsline Contact Email: Contact Phone: (None) |
| Friendly reminder: Click here to read some tips. | |
USAOnlineClassifieds > Internet Services > Other Internet Services
© 2024 USAOnlineClassifieds.com
USNetAds.com | GetJob.us | CANetAds.com | UKAdsList.com | AUNetAds.com | INNetAds.com | CNNetAds.com | Hot-Web-Ads.com
2024-12-26 (0.389 sec)